<strong>ARVO</strong> 2013 Annual Meeting Abstracts by Scientific Section/Group - <strong>Cornea</strong>in HaCaT cells.The excipients did not interfere with effects of BMP-7 and also didnot affect cell viability.Conclusions: BMP-7 with excipients has the ability to reducefibrosis and also the excipients contributed to the stabilization ofBMP-7. As such, it seems possible that this technology can beapplied to eye drops and become a new innovative treatment inpharmaceutical markets.Commercial Relationships: Jin-Wook Jang, None; Hansoo Kim,None; Chan-Young Cho, None; Jinkuk Kim, None; Ju-WoongJang, None; Young-Sik Kim, None; Ynag-je Cho, NoneSupport: 10037842 (Ministry of Knowledge Economy, Repulic ofKorea)Program Number: 3881 Poster Board Number: D0125Presentation Time: 2:45 PM - 4:30 PMGalectin-3 Enhanced Epithelialization in Explanted Monkey<strong>Cornea</strong>s with Alkali BurnAtsuko Fujii 1, 2 , Thomas R. Shearer 2 , Mitsuyoshi Azuma 1, 2 .1 Laboratory of Ocular Sciences, Senju Pharmaceutical Co, Ltd.,Beaverton, OR; 2 Department of Integrative Biosciences, OregonHealth & Science University, Portland, OR.Purpose: Following an injury leading to the loss of the cornealepithelium, the remaining epithelial cells immediately attempt toclose the defect. Poor healing of epithelial wounds is a major clinicalproblem, leading to persistent epithelial defects and ulceration. Wepreviously showed that carbohydrate-binding protein galectin-3 (Gal-3) enhanced wound closure in explanted monkey corneas laceratedby n-heptanol. Alkali injuries of the eye often cause extensivedamage to the cornea due to rapid penetration and damage to deeperocular structures. The purpose of the present experiment was to studyGal-3 in the more severe alkali burn model, and to compare results tothe n-heptanol model.Methods: An alkali burn was created by a 60 sec application of a 7.5mm diameter filter disc soaked in 1N sodium hydroxide onto thecentral cornea of enucleated monkey eyes. The corneas were thenexcised, incubated for various times with or without recombinantGal-3, and stained with 1% sodium fluorescein. <strong>Cornea</strong>l woundclosure was quantified by digital image analysis.Results: After an alkali burn, the corneal wound area became smallerin a time-dependent manner. Exogenous recombinant Gal-3 enhancedthis wound closure to the same extent as in corneas wounded with n-heptanol. However, data suggested that the rates of healing weredifferent in the two models.Conclusions: Exogenous Gal-3 showed a beneficial effect on closureof wounds caused by either alkali or n-heptanol. In both cases, thismay be because Gal-3 binds to ECMs such as laminin and collagenand promotes lamellipodia formation by cross-linking to α3 integrin.Although initial cytokines released from local cells may be differentin our two chemical models, the results indicate that Gal-3 may be acandidate drug to enhance epithelialization in human cornea damagedby variable causes.Dr. Shearer receives a research contract and consulting fees from, andDr. Azuma and Ms. Fujii are employees of, Senju Pharmaceutical Co.Ltd.Commercial Relationships: Atsuko Fujii, Senju PharmaceuticalCo., Ltd. (E); Thomas R. Shearer, Senju Pharmaceutical Co., Ltd.(F), Senju Pharmaceutical Co., Ltd. (C); Mitsuyoshi Azuma, SenjuPharmaceutical Co., Ltd. (E)Program Number: 3882 Poster Board Number: D0126Presentation Time: 2:45 PM - 4:30 PMMicroRNA-182 Inhibits Human <strong>Cornea</strong>l Epithelial CellProliferation and MigrationDongsheng Yan 1, 2 , Xiaoyan Chen 1, 2 , Jiao Wang 1, 2 , Lili Tu 1, 2 .1 School of Optometry and Ophthalmology, Wenzhou MedicalCollege, Wenzhou, China; 2 State Key Laboratory Cultivation Baseand Key Laboratory of Vision Science, Ministry of Health of P. R.China, Zhejiang Provincial Key Laboratory of Ophthalmology andOptometry, Wenzhou, China.Purpose: MicroRNAs (miRNAs) are endogenous short (~22)nucleotide RNAs which inhibit protein translation through binding totarget mRNAs. Recent studies have demonstrated that miR-182 canregulate tumor cell proliferation and migration. The role of miR-182in corneal wound healing, however, remains unclear. In the presentstudy, we investigated the function of miR-182 in human cornealepithelial cells.Methods: Realtime RT-PCR was performed to detect the expressionof miR-182 in mouse corneal epithelium during wound healingprocess. Human corneal epithelial cells were transfected with miR-34a. MTS and wound-healing assay was carried out to evaluate theeffect of miR-182 on human corneal epithelial cell proliferation andmigration, respectively. The expression of c-Met protein wasdetermined by Western blotting.Results: miR-182 was downregulated during corneal wound healingprocess. Transfection of miR-182 into human corneal epithelial cellsled to a significant decrease in cell proliferation and migration. miR-182 downregulated the expression of c-Met by Western blot analysis.Conclusions: Our results demonstrated that miR-182 inhibitedhuman corneal epithelial cell proliferation and migration bydownregulation of c-Met. This indicates that miR-182 may play animportant role in corneal wound healing process.Commercial Relationships: Dongsheng Yan, None; XiaoyanChen, None; Jiao Wang, None; Lili Tu, NoneSupport: National Natural Science Foundation of China(81071682&81272286)Program Number: 3883 Poster Board Number: D0127Presentation Time: 2:45 PM - 4:30 PMThe effects of IL-6 receptor blockade on gene expressions inexperimental corneal alkali burnSatoshi Sugaya, Tohru Sakimoto, Ai Yamada, Takako Ohnishi, AkikoIshimori, Mitsuru Sawa. Nihon University school of medicine,Tokyo, Japan.Purpose: Using experimental corneal alkali burn model, wepreviously reported the suppressive effect of topical instillation ofanti-Interleukin-6 receptor (IL-6R) antibody on infiltrations ofinflammatory cells. Using this model, we investigated the geneexpressions of inflammation-related factors and chemotactic factors.Methods: Unilateral eye of corneal alkali burn was made using afilter paper dipped in 1 N NaOH solution using BALB/c mice. Threeeyes of 3 mice were treated by topical instillation of anti-IL-6Rantibody solution (MR16-1, 2 µg/µL) from day 5 to day 28 afterwounding. (MR16-1 group)(from day 5 to day 14; 3 times/day, fromday 15 to day 28; 2 times/day) The control group (3 eyes of 3 mice,PBS group) underwent topical 0.01M PBS (pH 7.4) solution. Themice were euthanatized on day 28 and 2-μm-thick sections weremade. <strong>Cornea</strong>l stroma section was made using laser capturemicrodissection system, and total RNA in the specimens wasdetermined by quantitative PCR array method (Mouse Th17Response Array, QIAGEN).Results: In MR16-1 group, MMP (matrix metalloproteinase)-13(6.39±3.54; mean ± SD) expression was decreased by six timescompared with that in PBS group. The chemotactic factors ofmacrophage, MCP (monocyte chemotactic protein)-1 (5.83±1.95)©2013, Copyright by the Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Go to iovs.org to access the version of record. For permissionto reproduce any abstract, contact the <strong>ARVO</strong> Office at arvo@arvo.org.
<strong>ARVO</strong> 2013 Annual Meeting Abstracts by Scientific Section/Group - <strong>Cornea</strong>and CCL22 (2.78±0.43), were decreased in MR16-1 group comparedwith those in PBS group. In MR16-1 group, IL-17RE, the receptorfor IL-17, was higher two times values than that in PBS group(2.37±0.15).Conclusions: Anti-inflammatory effect of topical instillation of anti-IL-6R antibody could be caused by the suppression of chemokinesand MMP. Because IL-17 producing cells are induced by IL-6signaling, the up-regulation of IL-17R by IL-6R blockade may havethe relationship with IL-6R signal transduction.Commercial Relationships: Satoshi Sugaya, None; TohruSakimoto, None; Ai Yamada, None; Takako Ohnishi, None;Akiko Ishimori, None; Mitsuru Sawa, HOYA Co. (F), SantenPharmaceutical Co. (F)Program Number: 3884 Poster Board Number: D0128Presentation Time: 2:45 PM - 4:30 PMCD11b+GR1+ Myeloid Cells Promote Trigeminal GanglionNeurite Growth: Implications for <strong>Cornea</strong>l Nerve RegenerationSonal Gandhi, Joy Sarkar, Wallace Chamon, Shweta Chaudhary,Sapna Tibrewal, Yong-Soo Byun, Sarmad H. Jassim, AbhishekSharma, Neil Mohindra, Sandeep Jain. Ophthalmology and VisualSciences, University of Illinois at Chicago, Chicago, IL.Purpose: It is becoming increasingly clear that the nervous andinflammatory (myeloid) systems display considerable overlap in theirmolecular and cellular repertoire. Bone marrow-derived YFP+ cellsinfiltrate the cornea during nerve regeneration in thy1-YFP mouse.We characterized these cells and determined whether they promotetrigeminal ganglion (TG) cell neurite growth.Methods: Excimer laser annular keratectomy was performed in thy1-YFP+ mice and corneas were imaged to visualize regenerating nervesand infiltrating cells. Bone marrow cells (BMCs) were harvestedfrom naive thy1-YFP mice and a flow cytometry analyzer was usedto assess the expression levels of cell surface markers in the totalBMC population. Compartmental cultures of dissociated TG cellswere performed and sorted YFP+ cells (>95% pure) were co-culturedin the side compartments with neurites to determine theirneurotrophic effect.Results: Following annular keratectomy, YFP+ cells infiltrate thecornea and localize adjacent to transected nerves. These are bonemarrow-derived cells that share surface markers(CD11b+Gr1+Ly6C+Ly6G-F4/80low) with monocytic myeloidderivedsuppressor cells (MDSCs); thus, we call them YFP-MDSCs.They are CD11c, CD3e and MHC-II negative. YFP-MDSCssignificantly increase the growth of TG neurites and make physicalcontact with neurites. When cultured in a transwell with TG neurites,YFP-MDSCs express neurotrophins and secrete NGF and BDNF inthe conditioned media.Conclusions: CD11b+Gr1+ myeloid cells promote neurite growth inTG cells. These cells infiltrate the cornea after nerve transectionsurgery and interact with the regenerating nerves; thus they maypromote reinnervation by their neurotrophic action. One mechanismby which these cells promote neurite growth is by secretion ofneurotrophins.Commercial Relationships: Sonal Gandhi, None; Joy Sarkar,None; Wallace Chamon, None; Shweta Chaudhary, None; SapnaTibrewal, None; Yong-Soo Byun, None; Sarmad H. Jassim, None;Abhishek Sharma, None; Neil Mohindra, None; Sandeep Jain,PCT/US20/51562 (P)Support: NIH Grant EY018874Program Number: 3885 Poster Board Number: D0129Presentation Time: 2:45 PM - 4:30 PMSemaphorin 7a actions on nerves and myeloid cells in the corneapromote nerve regeneration, thus linking neuronal and myeloidsystemsSarmad H. Jassim, Abed Namavari, Shweta Chaudhary, SapnaTibrewal, Yong-Soo Byun, Sonal Gandhi, Neil Mohindra, Hyun Lee,Joy Sarkar, Sandeep Jain. Ophthalmology and Visual Sciences,University of Illinois at Chicago, Chicago, IL.Purpose: We determined Sema7a localization and quantity in naivecorneas and during nerve regeneration after lamellar flap surgery. Wealso performed structure-function analyses of Sema7a to determinewhether peptides that span RGD integrin-binding or RTS disintegrinmotifs selectively influence neuroregeneration.Methods: Immunolocalization and Western blot analyses wereperformed to evaluate the abundance of Sema7a in naive corneas andcorneas undergoing nerve regeneration after lamellar corneal surgeryin thy1-YFP+ neurofluorescent mice. We used compartmentalcultures of dissociated trigeminal ganglion cells to determine theeffect of Sema7a exposure on neurite outgrowth in vitro. Finally, aSema7a pellet was implanted under the corneal flap after lamellartransection surgery to determine the neuronal and inflammatoryeffects of Sema7a supplementation in vivo. We synthesized N-acetylated, C-amidated RGD- or RTS-containing peptides derivedfrom the Sema7a sequence and determined the number of dissociatedTG cells that adhered to collagen coated culture plates whenincubated with the peptides.Results: Sema7a is expressed in the cornea, mainly concentrated inthe epithelium with less expression in the stroma. <strong>Cornea</strong>l Sema7aexpression increases after nerve transecting lamellar surgery and islocalized near the regenerating nerve fronds. Sema7a induces neuritegrowth in vitro as potently as NGF. Exposure of trigeminal neuritesto Sema7a (20 nM) in the side compartment significantly increasedneurite length. The implanted Sema7a pellet significantly increasedYFP+ cell (CD11b+GR1+ immature myeloid derived suppressorcells) influx into the cornea as well as increased corneal nerve length.In contrast to 7A-RGD peptide, 7A-RTS peptide does not stimulateneurite growth but it reduces adhesion of neurons to collagen surface.Conclusions: Sema7a is constitutively expressed in the cornea andpotently stimulates nerve regeneration and influx of immaturemyeloid cell. Sema7a peptides spanning integrin-binding motifs(RGD or RTS) selectively influence neuroregeneration. This immunesemaphorin links nerve regeneration and myeloid systems in thecornea.Commercial Relationships: Sarmad H. Jassim, None; AbedNamavari, None; Shweta Chaudhary, None; Sapna Tibrewal,None; Yong-Soo Byun, None; Sonal Gandhi, None; NeilMohindra, None; Hyun Lee, None; Joy Sarkar, None; SandeepJain, PCT/US20/51562 (P)Support: NIH Grant EY018874Program Number: 3886 Poster Board Number: D0130Presentation Time: 2:45 PM - 4:30 PMThe Role of Heat Shock Protein 27 and Signal TransductionPathway of its Phosphorylation in <strong>Cornea</strong>l Epithelial WoundHealingJae Yong Kim, Soon-Suk Kang, In Seok Song, Eun-Soon Kim,Myoung Joon Kim, Hungwon Tchah. Ophthalmology, University ofUlsan College of Medicine, Asan Medical Center, Seoul, Republic ofKorea.Purpose: To investigate the role of heat shock protein 27 (HSP27)and signal transduction pathway of its phosphorylation in the woundhealing of cultured corneal epithelial cells.Methods: study 1) The scramble small interfering RNA (siRNA) andsiRNA against the HSP27 were created. The cultured corneal©2013, Copyright by the Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Go to iovs.org to access the version of record. For permissionto reproduce any abstract, contact the <strong>ARVO</strong> Office at arvo@arvo.org.
- Page 2 and 3:
ARVO 2013 Annual Meeting Abstracts
- Page 4 and 5:
ARVO 2013 Annual Meeting Abstracts
- Page 6 and 7:
ARVO 2013 Annual Meeting Abstracts
- Page 8 and 9:
ARVO 2013 Annual Meeting Abstracts
- Page 10:
ARVO 2013 Annual Meeting Abstracts
- Page 13 and 14:
ARVO 2013 Annual Meeting Abstracts
- Page 16 and 17:
ARVO 2013 Annual Meeting Abstracts
- Page 18 and 19:
ARVO 2013 Annual Meeting Abstracts
- Page 20 and 21:
ARVO 2013 Annual Meeting Abstracts
- Page 22 and 23:
ARVO 2013 Annual Meeting Abstracts
- Page 24 and 25:
ARVO 2013 Annual Meeting Abstracts
- Page 26 and 27:
ARVO 2013 Annual Meeting Abstracts
- Page 28 and 29:
ARVO 2013 Annual Meeting Abstracts
- Page 30 and 31:
ARVO 2013 Annual Meeting Abstracts
- Page 32 and 33:
ARVO 2013 Annual Meeting Abstracts
- Page 34 and 35:
ARVO 2013 Annual Meeting Abstracts
- Page 36 and 37:
ARVO 2013 Annual Meeting Abstracts
- Page 38 and 39:
ARVO 2013 Annual Meeting Abstracts
- Page 40 and 41:
ARVO 2013 Annual Meeting Abstracts
- Page 42 and 43:
ARVO 2013 Annual Meeting Abstracts
- Page 44 and 45:
ARVO 2013 Annual Meeting Abstracts
- Page 46 and 47:
ARVO 2013 Annual Meeting Abstracts
- Page 48 and 49:
ARVO 2013 Annual Meeting Abstracts
- Page 50 and 51:
ARVO 2013 Annual Meeting Abstracts
- Page 52 and 53:
ARVO 2013 Annual Meeting Abstracts
- Page 54 and 55:
ARVO 2013 Annual Meeting Abstracts
- Page 56 and 57:
ARVO 2013 Annual Meeting Abstracts
- Page 58 and 59:
ARVO 2013 Annual Meeting Abstracts
- Page 60 and 61:
ARVO 2013 Annual Meeting Abstracts
- Page 62 and 63:
ARVO 2013 Annual Meeting Abstracts
- Page 64 and 65:
ARVO 2013 Annual Meeting Abstracts
- Page 66 and 67:
ARVO 2013 Annual Meeting Abstracts
- Page 68 and 69:
ARVO 2013 Annual Meeting Abstracts
- Page 70 and 71:
ARVO 2013 Annual Meeting Abstracts
- Page 72 and 73:
ARVO 2013 Annual Meeting Abstracts
- Page 74 and 75:
ARVO 2013 Annual Meeting Abstracts
- Page 76 and 77:
ARVO 2013 Annual Meeting Abstracts
- Page 78 and 79:
ARVO 2013 Annual Meeting Abstracts
- Page 80 and 81:
ARVO 2013 Annual Meeting Abstracts
- Page 82 and 83:
ARVO 2013 Annual Meeting Abstracts
- Page 84 and 85:
ARVO 2013 Annual Meeting Abstracts
- Page 86 and 87:
ARVO 2013 Annual Meeting Abstracts
- Page 88 and 89:
ARVO 2013 Annual Meeting Abstracts
- Page 90 and 91:
ARVO 2013 Annual Meeting Abstracts
- Page 92 and 93:
ARVO 2013 Annual Meeting Abstracts
- Page 94 and 95:
ARVO 2013 Annual Meeting Abstracts
- Page 96 and 97:
ARVO 2013 Annual Meeting Abstracts
- Page 98 and 99:
ARVO 2013 Annual Meeting Abstracts
- Page 100 and 101:
ARVO 2013 Annual Meeting Abstracts
- Page 102 and 103:
ARVO 2013 Annual Meeting Abstracts
- Page 104 and 105:
ARVO 2013 Annual Meeting Abstracts
- Page 106 and 107:
ARVO 2013 Annual Meeting Abstracts
- Page 108 and 109:
ARVO 2013 Annual Meeting Abstracts
- Page 110 and 111:
ARVO 2013 Annual Meeting Abstracts
- Page 112 and 113:
ARVO 2013 Annual Meeting Abstracts
- Page 114 and 115:
ARVO 2013 Annual Meeting Abstracts
- Page 116 and 117:
ARVO 2013 Annual Meeting Abstracts
- Page 118 and 119:
ARVO 2013 Annual Meeting Abstracts
- Page 120 and 121:
ARVO 2013 Annual Meeting Abstracts
- Page 122 and 123:
ARVO 2013 Annual Meeting Abstracts
- Page 124 and 125:
ARVO 2013 Annual Meeting Abstracts
- Page 126 and 127:
ARVO 2013 Annual Meeting Abstracts
- Page 128 and 129:
ARVO 2013 Annual Meeting Abstracts
- Page 130 and 131:
ARVO 2013 Annual Meeting Abstracts
- Page 132 and 133:
ARVO 2013 Annual Meeting Abstracts
- Page 134 and 135:
ARVO 2013 Annual Meeting Abstracts
- Page 136 and 137:
ARVO 2013 Annual Meeting Abstracts
- Page 138 and 139:
ARVO 2013 Annual Meeting Abstracts
- Page 140 and 141:
ARVO 2013 Annual Meeting Abstracts
- Page 142 and 143:
ARVO 2013 Annual Meeting Abstracts
- Page 144 and 145:
ARVO 2013 Annual Meeting Abstracts
- Page 146 and 147:
ARVO 2013 Annual Meeting Abstracts
- Page 148 and 149:
ARVO 2013 Annual Meeting Abstracts
- Page 150 and 151:
ARVO 2013 Annual Meeting Abstracts
- Page 152 and 153:
ARVO 2013 Annual Meeting Abstracts
- Page 154 and 155:
ARVO 2013 Annual Meeting Abstracts
- Page 156 and 157:
ARVO 2013 Annual Meeting Abstracts
- Page 158 and 159:
ARVO 2013 Annual Meeting Abstracts
- Page 160 and 161:
ARVO 2013 Annual Meeting Abstracts
- Page 162 and 163:
ARVO 2013 Annual Meeting Abstracts
- Page 164 and 165:
ARVO 2013 Annual Meeting Abstracts
- Page 166 and 167:
ARVO 2013 Annual Meeting Abstracts
- Page 168 and 169:
ARVO 2013 Annual Meeting Abstracts
- Page 170 and 171:
ARVO 2013 Annual Meeting Abstracts
- Page 172 and 173:
ARVO 2013 Annual Meeting Abstracts
- Page 174 and 175:
ARVO 2013 Annual Meeting Abstracts
- Page 176 and 177:
ARVO 2013 Annual Meeting Abstracts
- Page 178 and 179:
ARVO 2013 Annual Meeting Abstracts
- Page 180 and 181:
ARVO 2013 Annual Meeting Abstracts
- Page 182 and 183:
ARVO 2013 Annual Meeting Abstracts
- Page 184 and 185:
ARVO 2013 Annual Meeting Abstracts
- Page 186 and 187:
ARVO 2013 Annual Meeting Abstracts
- Page 188 and 189:
ARVO 2013 Annual Meeting Abstracts
- Page 190 and 191:
ARVO 2013 Annual Meeting Abstracts
- Page 192 and 193:
ARVO 2013 Annual Meeting Abstracts
- Page 194 and 195: ARVO 2013 Annual Meeting Abstracts
- Page 196 and 197: ARVO 2013 Annual Meeting Abstracts
- Page 198 and 199: ARVO 2013 Annual Meeting Abstracts
- Page 200 and 201: ARVO 2013 Annual Meeting Abstracts
- Page 202 and 203: ARVO 2013 Annual Meeting Abstracts
- Page 204 and 205: ARVO 2013 Annual Meeting Abstracts
- Page 206 and 207: ARVO 2013 Annual Meeting Abstracts
- Page 208 and 209: ARVO 2013 Annual Meeting Abstracts
- Page 210 and 211: ARVO 2013 Annual Meeting Abstracts
- Page 212 and 213: ARVO 2013 Annual Meeting Abstracts
- Page 214 and 215: ARVO 2013 Annual Meeting Abstracts
- Page 216 and 217: ARVO 2013 Annual Meeting Abstracts
- Page 218 and 219: ARVO 2013 Annual Meeting Abstracts
- Page 220 and 221: ARVO 2013 Annual Meeting Abstracts
- Page 222 and 223: ARVO 2013 Annual Meeting Abstracts
- Page 224 and 225: ARVO 2013 Annual Meeting Abstracts
- Page 226 and 227: ARVO 2013 Annual Meeting Abstracts
- Page 228 and 229: ARVO 2013 Annual Meeting Abstracts
- Page 230 and 231: ARVO 2013 Annual Meeting Abstracts
- Page 232 and 233: ARVO 2013 Annual Meeting Abstracts
- Page 234 and 235: ARVO 2013 Annual Meeting Abstracts
- Page 236 and 237: ARVO 2013 Annual Meeting Abstracts
- Page 238 and 239: ARVO 2013 Annual Meeting Abstracts
- Page 240 and 241: ARVO 2013 Annual Meeting Abstracts
- Page 242 and 243: ARVO 2013 Annual Meeting Abstracts
- Page 246 and 247: ARVO 2013 Annual Meeting Abstracts
- Page 248 and 249: ARVO 2013 Annual Meeting Abstracts
- Page 250 and 251: ARVO 2013 Annual Meeting Abstracts
- Page 252 and 253: ARVO 2013 Annual Meeting Abstracts
- Page 254 and 255: ARVO 2013 Annual Meeting Abstracts
- Page 256 and 257: ARVO 2013 Annual Meeting Abstracts
- Page 258 and 259: ARVO 2013 Annual Meeting Abstracts
- Page 260 and 261: ARVO 2013 Annual Meeting Abstracts
- Page 262 and 263: ARVO 2013 Annual Meeting Abstracts
- Page 264 and 265: ARVO 2013 Annual Meeting Abstracts
- Page 266 and 267: ARVO 2013 Annual Meeting Abstracts
- Page 268 and 269: ARVO 2013 Annual Meeting Abstracts
- Page 270 and 271: ARVO 2013 Annual Meeting Abstracts
- Page 272 and 273: ARVO 2013 Annual Meeting Abstracts
- Page 274 and 275: ARVO 2013 Annual Meeting Abstracts
- Page 276 and 277: ARVO 2013 Annual Meeting Abstracts
- Page 278 and 279: ARVO 2013 Annual Meeting Abstracts
- Page 280 and 281: ARVO 2013 Annual Meeting Abstracts
- Page 282 and 283: ARVO 2013 Annual Meeting Abstracts
- Page 284 and 285: ARVO 2013 Annual Meeting Abstracts
- Page 286 and 287: ARVO 2013 Annual Meeting Abstracts
- Page 288 and 289: ARVO 2013 Annual Meeting Abstracts
- Page 290 and 291: ARVO 2013 Annual Meeting Abstracts
- Page 292 and 293: ARVO 2013 Annual Meeting Abstracts
- Page 294 and 295:
ARVO 2013 Annual Meeting Abstracts
- Page 296 and 297:
ARVO 2013 Annual Meeting Abstracts
- Page 298 and 299:
ARVO 2013 Annual Meeting Abstracts
- Page 300 and 301:
ARVO 2013 Annual Meeting Abstracts
- Page 302 and 303:
ARVO 2013 Annual Meeting Abstracts
- Page 304 and 305:
ARVO 2013 Annual Meeting Abstracts
- Page 306 and 307:
ARVO 2013 Annual Meeting Abstracts
- Page 308 and 309:
ARVO 2013 Annual Meeting Abstracts
- Page 310 and 311:
ARVO 2013 Annual Meeting Abstracts
- Page 312 and 313:
ARVO 2013 Annual Meeting Abstracts
- Page 314 and 315:
ARVO 2013 Annual Meeting Abstracts
- Page 316 and 317:
ARVO 2013 Annual Meeting Abstracts
- Page 318 and 319:
ARVO 2013 Annual Meeting Abstracts
- Page 320 and 321:
ARVO 2013 Annual Meeting Abstracts
- Page 322 and 323:
ARVO 2013 Annual Meeting Abstracts
- Page 324 and 325:
ARVO 2013 Annual Meeting Abstracts
- Page 326 and 327:
ARVO 2013 Annual Meeting Abstracts
- Page 328 and 329:
ARVO 2013 Annual Meeting Abstracts
- Page 330 and 331:
ARVO 2013 Annual Meeting Abstracts
- Page 332 and 333:
ARVO 2013 Annual Meeting Abstracts
- Page 334 and 335:
ARVO 2013 Annual Meeting Abstracts
- Page 336 and 337:
ARVO 2013 Annual Meeting Abstracts
- Page 338 and 339:
ARVO 2013 Annual Meeting Abstracts
- Page 340 and 341:
ARVO 2013 Annual Meeting Abstracts
- Page 342 and 343:
ARVO 2013 Annual Meeting Abstracts
- Page 344 and 345:
ARVO 2013 Annual Meeting Abstracts
- Page 346 and 347:
ARVO 2013 Annual Meeting Abstracts
- Page 348 and 349:
ARVO 2013 Annual Meeting Abstracts
- Page 350 and 351:
ARVO 2013 Annual Meeting Abstracts
- Page 352 and 353:
ARVO 2013 Annual Meeting Abstracts
- Page 354 and 355:
ARVO 2013 Annual Meeting Abstracts
- Page 356 and 357:
ARVO 2013 Annual Meeting Abstracts
- Page 358 and 359:
ARVO 2013 Annual Meeting Abstracts
- Page 360 and 361:
ARVO 2013 Annual Meeting Abstracts
- Page 362 and 363:
ARVO 2013 Annual Meeting Abstracts
- Page 364 and 365:
ARVO 2013 Annual Meeting Abstracts
- Page 366 and 367:
ARVO 2013 Annual Meeting Abstracts
- Page 368 and 369:
ARVO 2013 Annual Meeting Abstracts
- Page 370 and 371:
ARVO 2013 Annual Meeting Abstracts
- Page 372 and 373:
ARVO 2013 Annual Meeting Abstracts
- Page 374 and 375:
ARVO 2013 Annual Meeting Abstracts
- Page 376 and 377:
ARVO 2013 Annual Meeting Abstracts
- Page 378 and 379:
ARVO 2013 Annual Meeting Abstracts
- Page 380 and 381:
ARVO 2013 Annual Meeting Abstracts
- Page 382 and 383:
ARVO 2013 Annual Meeting Abstracts